Leonardo Scapozza

Has grant

Full Professor

University of Geneva

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Leonardo Scapozza is a Full Professor at the University of Geneva in Switzerland. His research areas include therapeutic strategies for Duchenne Muscular Dystrophy, the role of natural products in inhibiting viral proteases, and the development of innovative methods for enhancing the oral delivery of biologics. His recent publications highlight advancements in protein degradation mechanisms and the effects of various compounds on cellular processes.

Recent Grants

Grant: Close

Adenosine 2A receptor reactivation by positive allosteric mod-ulators as a new therapeutic venue for unmet medical need in chronic inflammation

Open Date: 2022-09-01

Close Date: 2024-02-01

Grant: Close

A2AR negative allosteric modulators for cancer immunotherapy: validation of lead candidate

Open Date: 2020-12-01

Close Date: 2022-06-01

Grant: Close

G2B Gut-To-Blood: a platform for oral systemic delivery of targeted therapies

Open Date: 2020-01-01

Close Date: 2023-01-01

Grant: Close

Duchenne muscular dystrophy: Phenotyping and validation of better murine models for improving preclinical research and clinical translation

Open Date: 2020-01-01

Close Date: 2022-01-01

Grant: Close

Repurposing drugs to combat fibrosis in Duchenne patients: Pharmacotherapy studies in a murine model with enhanced fibrosis

Open Date: 2020-01-01

Close Date: 2022-01-01

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (23)

Simon Braun

Assistant Professor

University of Geneva

SWITZERLAND

Leonardo Scapozza

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (14)

A Hypothesized Therapeutic Role of (Z)-Endoxifen in Duchenne Muscular Dystrophy (DMD)

A Novel, Cell-Compatible Hyaluronidase Activity Assay Identifies Dextran Sulfates and Other Sulfated Polymeric Hydrocarbons as Potent Inhibitors for CEMIP

Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model

Compound K14 inhibits bacterial killing and protease activity in Dictyostelium discoideum phagosomes

Identification of Natural Products Inhibiting SARS-CoV-2 by Targeting Viral Proteases: A Combined in Silico and in Vitro Approach

CEMIP (HYBID, KIAA1199): structure, function and expression in health and disease

Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog pathway inhibitor-1

Challenges and Opportunities in the Oral Delivery of Recombinant Biologics

In silico investigation of cytochrome bc1 molecular inhibition mechanism against Trypanosoma cruzi

Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase

5-ethyl-2’-deoxyuridine fragilizes Klebsiella pneumoniae outer wall and facilitates intracellular killing by phagocytic cells

Discovery of anti-Formin-like 1 protein (FMNL1) antibodies in membranous nephropathy and other glomerular diseases.

Correction to "Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase".

Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase.

Collaborators (23)

Simon Braun

Johannes Kirchmair

Pierre Cosson

Alfonso Zambon

Sascha Hoogendoorn

Maxime CULOT

Peter Goekjian

Marco Prunotto

Fabien Gosselet

Luca Mologni

Andreas Boland

Cédric Schneider

Magali Zeisser Labouebe

Julien Orts

David Gueyrard

Thierry SOLDATI

Marie Jose Abi Saad

Ulrike Grienke

Andrea Danani

Judith Rollinger

Yogeshvar Kalia

Jonathan P. Sleeman

Yibo Wu

Make your next move.